Provalis PLC - Disposal

RNS Number:3660C
Provalis PLC
13 December 1999


          Provalis disposes of its remaining non-core businesses and
                refocuses its Healthcare Division on sales and
                     marketing of ethical pharmaceuticals

Provalis plc today announces the latest step in its restructuring to an
integrated healthcare company focusing on Pharmaceutical sales and marketing,
Medical Diagnostics and Therapeutic R&D.

The Company has agreed to sell certain assets used by Chancellor Group Limited
and Consolidated Chemicals Limited, its non-core pharmaceutical businesses, to
Ayrton Saunders Ltd for #760,000.

This sale, completion of which will, under the terms of the agreement, take
place on 4th January 2000, will allow Provalis' Healthcare Division to focus
on its retained ethical pharmaceuticals sales and marketing business, which
has been trading profitably since June 1999.  These profits result from
stronger sales, improved cost management and contributions from product
launches.  Following this sale, Provalis' manufacturing facilities at Wrexham,
North Wales, will be closed, with the retained ethical pharmaceutical sales
and marketing business being managed from Provalis' centralised head office at
Deeside.

Dr Phil Gould, Chief Executive Officer of Provalis, commented: "We announced
our intention to dispose of Chancellor and Consolidated at the announcement of
our Preliminary results in October, in line with our new strategy for
Provalis.  We are now ideally positioned to grow our profitable Healthcare
Division, to focus on the launch of our core medical diagnostic products and
to exploit the value of its therapeutic product portfolio, particularly in
vaccines."

For further information, please contact:

Lee Greenbury, Provalis plc                Tel: 01244 833402
                                           
Emily Bruning, Shandwick International     Tel: 0171 905 2448/2442


END
DISTMBRBLLIBBML

Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024